Original articles

2024

Günther M, Schuler M, Hentschel L, Salm H, Schmitz M-T, Jaehde U. Medication Risks and Their Association with Patient-Reported Outcomes in Inpatients with Cancer. Cancers. 2024; 16(11):2110.

2023

Arruda J, Schälte Y, Peiter C, Teplytska O, Jaehde U, Hasenauer J. An amortized approach to non-linear mixed-effects modeling based on neural posterior estimation. bioRxiv 2023.08.22.554273 (preprint)

Ge F, Wang Y, Sharma A, Yang Y, Liu H, Essler M, Jaehde U, Schmidt-Wolf IGH. Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt’s lymphoma. Int J Mol Sci. 2023; 24: 12476

Karsten Dafonte K, Weber L, Chmielewski F, Böhmer AM, Lutz P, Hartmann G, Jaehde U, Coenen M. Dose Recommendations for Common Drugs in Patients with Liver Cirrhosis: A Systematic Literature Review. Clin Drug Investig. 2023; 43: 475-502.

Bilal M, Zoller M, Fuhr U, Jaehde U, Ullah S, Liebchen U, Büsker S, Zander J, Babouee Flury B, Taubert M. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients. Antimicrob Agents Chemother. 2023; 67: e0030923.

Günther M, Hentschel L, Schuler M, Müller T, Schütte K, Ko YD, Schmidt-Wolf I, Jaehde U. Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers. BMC Cancer 2023; 23: 629

Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaur I, Larcher-Senn J, Buck S, Mathijssen RHJ, Jaehde U, Gillessen S, Joerger M. Randomized phase 2 Cabazitaxel dose individualization and Neutropenia prevention Trial (CAINTA) in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2023; 29: 1887-1893

Schmulenson E, Zimmermann N, Müller L, Kapsa S, Sihinevich I, Jaehde U. Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil. Cancer Med 2023; 12: 2580-2589

Haerdtlein A, Debold E, Rottenkolber M, Boehmer AM, Pudritz YM, Shahid F, Gensichen J, Dreischulte T. Which Adverse Events and Which Drugs Are Implicated in Drug-Related Hospital Admissions? A Systematic Review and Meta-Analysis. J Clin Med 2023; 12: 1320

2022

Barnert A-K, Hofmann P, Liekweg A, Kunze A, Scheid C, Hermes-Moll K, Osburg S,  Jaehde U. Akzeptanz eines onkologischen Addendums zur Anwendung des Bundeseinheitlichen Medikationsplans in der oralen Tumortherapie. Z Evid Fortbild Qual Gesundhwes 2022; 175: 29-42

Weber L, Langebrake C, Picksak G, Schöning T, Schulze I, Jaehde U. Medication errors in cancer therapy: Reports from German hospital pharmacies between 2008 and 2019. J Oncol Pharm Pract 2022; 10781552221135130. Online ahead of print

Ortland I, Mendel Ott M, Kowar M, Sippel C, Ko YD, Jacobs AH, Jaehde U. Medication risks in older patients (70 +) with cancer and their association with therapy-related toxicity. BMC Geriatr 2022; 22: 716

Haerdtlein A, Boehmer AM, Karsten Dafonte K, Rottenkolber M, Jaehde U, Dreischulte T. Prioritisation of Adverse Drug Events Leading to Hospital Admission and Occurring during Hospitalisation: A RAND Survey. J Clin Med 2022; 11: 4254

Schmulenson E, Bovet C, Theurillat R, Decosterd LA, Largiadèr CR, Prost JC, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Joerger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88: 5336- 5347

Schmitz K, Lenssen R, Rückbeil M, Berning D, Thomeczek C, Brokmann JC, Jaehde U, Eisert A. The WHO High 5s project: medication reconciliation in a German university hospital. A prospective observational cohort study. Z Evid Fortbild Qual Gesundhwes 2022; 168: 27-32

2021

Mc Laughlin AM, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland SL, Huitema ADR, Steeghs N, Müller L, Fuxius S, Illerhaus G, Joerger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, for the ON-TARGET Study Consortium. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers 2021; 13: 6281

Vucur C, Wirtz DA, Weinhold L, Zipfel M, Schmid M, Schmidt-Wolf IG, Jaehde U. Drug-related problems in head and neck cancer patients identified by repeated medication reviews on consecutive therapy cycles. J Oncol Pharm Pract 2021; 27: 1439-1446

2020

Schmulenson E, Krolop L, Simons S, RIngsdorf S, Ko YD, Jaehde U. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach. Cancer Chemother Pharmacol 2020; 86: 435-444

Barakat AK, Scholl C, Steffens M, Brandenburg K, Ising M, Lucae S, Holsboer F, Laje G, Kalayda GV, Jaehde U, Stingl JC. Citalopram-induced Pathways Regulation and Tentative Treatment-Outcome-Predicting Biomarkers in Lymphoblastoid Cell Lines From Depression Patients. Transl Psychiatry 2020; 10: 210

Waltering I, Scheppe S, Kurth V, Hempel G, Jaehde U. Quality Indicators for Medication Reviews in Community Pharmacies. Z Evid Fortbild Qual Gesundhwes 2020;  153: 44-53

Möltgen S, Piumatti E, Massafra GM, Metzger S, Jaehde U, Kalayda GV. Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity. Cells 2020; 9: E1322

Li X, Junge L, Taubert M, von Georg A, Dahlinger D, Starke C, Frechen S, Stelzer C, Kinzig M, Sörgel F, Jaehde U, Töx U, Goeser T, Fuhr U. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. J Clin Pharmacol 2020; 11: 997-1005

Arshad U, Ploylearmsaeng SA, Karlsson MO, Doroshyenko O, Langer D, Schömig E, Kunze S, Güner SA, Skripnichenko R, Ullah S, Jaehde U, Fuhr U, Jetter A, Taubert M. Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. Cancer Chemother Pharmacol 2020; 85: 711-722

Ortland I, Mendel Ott M, Kowar M, Sippel C, Jaehde U, Jacobs AH, Ko YD. Comparing the performance of the CARG and the CRASH score for predicting toxicity in older patients in cancer. J Geriatr Oncol 2020; 11:997-1005

Dilruba S, Grondana A, Schiedel AC, Ueno NT, Bartholomeusz C, Cinatl J Jr, McLaughlin KM, Wass MN, Michaelis M, Kalayda GV. Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells 2020; 9: E515

2019

Bitter K, Pehe C, Krüger M, Heuer G, Quinke R, Jaehde U. Pharmacist-led medication reviews for geriatric residents in German long-term care facilities.  BMC Geriatr 2019; 19: 39

2018

Schlender JF, Teutonico D, Coboeken K, Schnizler K, Eissing T, Willmann S, Jaehde U, Stass H. A Physiologically- Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life. Clin Pharmacokinet 2018; 57: 1613-1634

Lenssen R, Schmitz K, Griesel C, Heidenreich A, Schulz JB, Trautwein C, Marx N, Fitzner C, Jaehde U, Eisert A. Comprehensive pharmaceutical care to prevent drug-related readmissions of dependent-living elderly patients: a randomized controlled trial. BMC Geriatr 2018; 18: 135

Kotz S, Kullmann M, Kalayda GV, Dyballa-Rukes N, Jaehde U, Metzger S. Optimized two-dimensional gel electrophoresis in an alkaline pH range improves the identification of intracellular CFDA-cisplatin-protein adducts in ovarian cancer cells. Electrophoresis. 2018; 39: 1488-1496

Sarin N, Engel F, Rothweiler F, Cinatl J, Michaelis M, Frötschl R, Fröhlich H, Kalayda GV. Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach. Int J Mol Sci. 2018; 19: 767

Buß I, Hamacher A, Sarin N, Kassack MU, Kalayda GV. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics 2018; 10: 414-425

Stojković T, Rose O, Woltersdorf R, Marinković V, Manser T, Jaehde U. Prospective systemic risk analysis of the dispensing process in German community pharmacies. Int J Health Plann Manage 2018; 33: e320-e332

2017

Schneider V, Chaib S, Spanier C, Knapp M, Moscvin V, Scordovillo L, Ewertz A, Jaehde U, Kalayda GV. Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level. AAPS J. 2017; 20: 9

Joerger M, Kraff S, Jaehde U, Hilger RA, Courtney JB, Cline DJ, Jog S, Baburina I, Miller MC, Salamone SJ. Validation of a commercial assay and decision support tool for routine paclitaxel therapeutic drug monitoring (TDM). Ther Drug Monit. 2017; 39: 617-624

Sarin N, Engel F, Kalayda GV, Mannewitz M, Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde U, Frötschl R. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. PLoS One 2017; 12: e0181081

Kalayda GV, Kullmann M, Galanski M, Gollos S. A fluorescent oxaliplatin derivative for investigation of oxaliplatin resistance using imaging techniques. J Biol Inorg Chem 2017; 22:1259-1304

Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen ZP. Semi-mechanistic bone marrow exhaustion pharmacokinetic/pharmacodynamic model for chemotherapy-induced cumulative neutropenia. J Pharmacol Exp Ther. 2017; 362: 347-358

Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U. Population modelling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics and clinical outcome in sunitinib-treated cancer patients. CPT Pharmacometrics Syst Pharmacol 2017; 6: 604-613

Rose O, Jaehde U, Köberlein-Neu J. Discrepancies between home medication and patient documentation in primary care. Res Social Adm Pharm 2017; 14: 340-346

van der Zanden LF, Vermeulen SH, Oskarsdottir A, Maurits JS, Diekstra MH, Ambert V, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia Donas J, Guarch Troyas R, Guchelaar HJ, Hartmann A, Hulsbergen-van de Kaa C, Jaehde U, Junker K, Martinez-Cardus A, Masson G, Oosterwijk-Wakka J, Radu MT, Rafnar T, Rodriguez-Antona C, Roessler M, Ruijtenbeek R, Stefansson K, Warren A, Wessels L, Eisen T, Kiemeney LA, Oosterwijk E. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity. Urol Oncol 2017; 35: 529.e9-529.e16

Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Sci Pharm 2017; 85: 8

Kaestner B, Spicher K, Jaehde U, Enzmann H. Effects of sorafenib and cisplatin on preneoplastic foci of altered hepatocytes in fetal turkey liver. Toxicol Res 2017; 6: 54-62

Stojković T, Marinović V, Jaehde U, Manser T. Using Failure Mode and Effects Analysis to Reduce Patient Safety Riscs Related to the Dispensing Process in the Community Pharmacy Setting. Res Social Adm Pharm 2017; 13: 1159-1166

2016

Köberlein-Neu J, Mennemann H, Hamacher S, Waltering I, Jaehde U, Schaffert C, Rose O. Interprofessional Medication Management in Patients with Multiple Morbidities. Dtsch Arztebl Int 2016; 113: 741-748

Hagelstein V, Ortland I, Wilmer A, Mitchell SA, Jaehde U. Validation of the German patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE). Ann Oncol 2016; 27: 2294-2299

Sarin N, Engel F, Kalayda GV, Frötschl R, Cinatl J Jr, Rothweiler F, Michaelis M, Fröhlich H, Jaehde U. Knowledge-based approach to identify key determinants of cisplatin sensitivity. Int J Clin Pharmacol Ther 2016; 55: 686-689

Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2016 Oct; 27:1895-1902

Atzler D, Schönhoff M, Cordts K, Ortland I, Hoppe J, Hummel FC, Gerloff C, Jaehde U, Jagodzinski A, Böger RH, Choe CU, Schwedhelm E. Oral supplementation with L-homoarginine in young volunteers. Br J Clin Pharmacol 2016; 82: 1477-1485

Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet 2016; 55: 1573-1589

Rose O, Mennemann H, John C, Lautenschläger M, Mertens-Keller D, Richling K, Waltering I, Hamacher S, Felsch M, Herich L, Czarnecki K, Schaffert C, Jaehde U, Köberlein-Neu J. Priority Setting and Influential Factors on Acceptance of Pharmaceutical Recommendations in Collaborative Medication Reviews in an Ambulatory Care Setting - Analysis of a Cluster Randomized Controlled Trial (WestGem-Study). PLoS One 2016; 11: e0156304

Wilhelm M, Mueller L, Miller MC, Link K, Holdenrieder S, Bertsch T, Kunzmann V, Stoetzer OJ, Suttmann I, Braess J, Birkmann J, Roessler M, Moritz B, Kraff S, Salamone SJ, Jaehde U. Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. Clin Colorectal Cancer 2016; 15: 381-388

Lenssen R, Heidenreich A, Schulz JB, Trautwein C, Fitzner C, Jaehde U, Eisert A. Analysis of drug-related problems in three departments of a German University hospital. Int J Clin Pharm 2016; 38: 119-126

2015

Vossen MG, Wenisch JM, Maier-Salamon A, Fritsch A, Saria K, Zuba C, Jilch S, Lemmerer R, Unger M, Jaehde U, Jäger W, Thalhammer F. Doripenem treatment during continuous renal replacement therapy. Antimicrob Agents Chemother 2015; 60: 1687-1694

Dilruba S, Michaelis M, Cinatl J, Kalayda GV. Relevance of subcellular localization of extracellular signal-regulated kinase 1/2 (ERK1/2) for cisplatin resistance. Int J Clin Pharmacol Ther 2015; 53(12):1041-1045

Kullmann M, Kotz S, Hellwig M, Kalayda GV, Metzger S, Jaehde U. GRP78 knockdown does not affect cytotoxicity of cisplatin in ovarian cancer cells. Int J Clin Pharmacol Ther 2015; 53: 1038-1040

Kullmann M, Kalayda GV, Hellwig M, Kotz S, Hilger RA, Metzger S, Jaehde U. Assessing the contribution of the two protein disulfide isomerases PDIA1 and PDIA3 to cisplatin resistance. J Inorg Biochem 2015; 153: 247-252

Suleiman AA, Frechen S, Scheffler M, Zander T, Nogova L, Kocher M, Jaehde U, Wolf J, Fuhr U. A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. AAPS J 2015; 17: 1483-1491

Kotz S, Kullmann M, Crone B, Kalayda GV, Jaehde U, Metzger S.Combination of two-dimensional gel electrophoresis and a fluorescent carboxyfluorescein diacetate labeled cisplatin analogue allows the identification of intracellular cisplatin-protein adducts Electrophoresis 2015; 36: 2811-2819

Kraff S, Lindauer A, Joerger M, Salamone SJ, Jaehde U. Excel®-Based Tool for Pharmacokinetically-Guided Dose Adjustment of Paclitaxel. Ther Drug Monit. 2015; 37: 725-732

Kraff S, Nieuweboer AJ, Mathijssen RH, Baty F, de Graan AJ, van Schaik RH, Jaehde U, Joerger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol 2015; 75: 975-983

Retlich S, Duval V, Graefe-Mody U, Friedrich C, Patel S, Jaehde U, Staab A. Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus. Clin Pharmacokinet 2015; 54: 737-750

Zabel R, Kullmann M, Kalayda GV, Jaehde U, Weber G. Optimized sample preparation strategy for the analysis of low-molecular-mass adducts of a fluorescent cisplatin analogue in cancer cell lines by CE-Dual-LIF. Electrophoresis 2015; 36: 509-517

Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, Ruehs H, Keyver-Paik MD, Rudlowski C, Weber S, Kiefer N, Poelcher ML, Thiesler T, Rostamzadeh B, Mallmann M, Schaefer N, Permantier M, Latten S, Kalff J, Thomale J, Jaehde U, Kuhn WC. HIPEC ROC I: A phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 2015; 136: 699-708

2014

Mross K, Scheulen M, Strumberg D, Kuhlmann J, Kanefendt F, Sörgel F, Jaehde U, Burkholder I, Moritz B, Büchert M. FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases - a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. Int J Clin Pharmacol Ther 2014; 52: 642-652

2013

Mohn C, Häcker HG, Hilger RA, Gütschow M, Jaehde U. Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin. Pharmazie 2013; 68: 622-627

Krolop L, Ko Y-D, Schwindt PF, Schumacher C, Fimmers R, Jaehde U. Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study. BMJ Open 2013; 3: e003139

Koch M, Krieger ML, Stölting D, Brenner N, Beier M, Jaehde U, Wiese M, Royer HD, Bendas G. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling. Biochem Pharmacol 2013; 85: 1077-1090

Schneider V, Krieger ML, Bendas G, Jaehde U, Kalayda GV. Contribution of intracelluar ATP to cisplatin resistance of tumor cells. J Biol Inorg Chem 2013; 18: 165-174

2012

Kalayda GV, Wagner CH, Jaehde U. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. J Inorg Biochem 2012; 116: 1-10

Rühs H, Becker A, Drescher A, Panetta JC, Pui C-H, Relling MV, Jaehde U. Population PK/PD Model of Homocysteine Concentrations after High-Dose Methotrexate Treatment in Patients with Acute Lymphoblastic Leukemia. PLoS One 2012; 7: e46015

Kanefendt F, Lindauer A, Mross L, Fuhr U, Jaehde U. Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker. J Pharm Biomed Anal 2012; 70: 485-491

Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, Beijnen JH, Jaehde U. Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring: A Pharmacokinetic-Pharmacodynamic Simulation Study. Clin Pharmacokinet 2012; 51: 607-617

Buss I, Kalayda GV, Lindauer A, Reithofer MR, Galanski M, Keppler BK, Jaehde U. Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues. J Biol Inorg Chem 2012; 17: 699–708

Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, Jaehde U. Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer 2012; 20: 2669-2677

Besançon OG, Tytgat GA, Meinsma R, Leen R, Hoebink J, Kalayda GV, Jaehde U, Caron HN, van Kuilenburg AB. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids. Cancer Lett 2012; 319: 23-30

2011

Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 2011; 19: 1009-1018

Döhler N, Krolop L, Ringsdorf S, Meier K, Ko YD, Kuhn W, Schwalbe O, Jaehde U. Task allocation in cancer medication management - integrating the pharmacist. Patient Educ Couns 2011; 83: 367-374

Buss I, Garmann D, Galanski M, Weber G, Kalayda GV, Keppler BK, Jaehde U. Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes? J Inorg Biochem 2011; 105: 709-717

2010

Retlich S, Duval V, Ring A, Staab A, Hüttner S, Jungnik A, Jaehde U, Dugi KA, Graefe-Mody U. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet 2010; 49: 829-840

Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 2010; 88: 643-651

Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A. Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010; 50: 873-85

Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, Dodos F, Sörgel F, Fuhr U, Jaehde U. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther 2010; 87: 601-608

Lindauer A, Eickhoff C, Kloft C, Jaehde U. Population pharmacokinetics of high-dose carboplatin in children and adults. Ther Drug Monit 2010; 32: 159-168

Krieger ML, Eckstein N, Schneider V, Koch M, Royer HD, Jaehde U, Bendas G. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm 2010; 389: 10-17

Rotte A, Garmann D, Buss I, Jaehde U. Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian carcinoma cells. Chemotherapy 2010; 56: 1-8

Swennen EL, Ummels V, Buss I, Jaehde U, Bast A, Dagnelie PC. ATP sensitizes H460 lung carcinoma cells to cisplatin-induced apoptosis. Chem Biol Interact 2010; 184: 338-345

Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Jaehde U, Reiter A, Naber KG, Rodamer M, Sörgel F. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.Br J Clin Pharmacol 2010; 69: 167-178

2009

Marqués-Gallego P, Contaldi S, den Dulk H, Monari M, Brouwer J, Jaehde U, Kalayda GV, Reedijk J. Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand. J Inorg Biochem 2009; 103: 1602-1608

Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos 2009; 30: 422-436

Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs 2009; 20: 396-402

Marqués-Gallego P, Kalayda GV, Jaehde U, Dulk H, Brouwer J, Reedijk J. Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands. J Inorg Biochem 2009; 103: 791-796

Lentz F, Drescher A, Lindauer A, Henke M, Hilger RA, Hartinger CG, Scheulen ME, Dittrich C, Keppler BK, Jaehde U, Central European Society for Anticancer Drug Research-EWIV. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.Anticancer Drugs 2009; 20: 97-103

Vezmar S, Schüsseler P, Becker A, Bode U, Jaehde U. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity.Pediatr Blood Cancer 2009; 52: 26-32

2008

Garmann D, Warnecke A, Kalayda GV, Kratz F, Jaehde U. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. J Control Release 2008; 131: 100-106

Kalayda GV, Wagner CH, Buss I, Reedijk J, Jaehde U. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 2008; 8: 175

Lindauer A, Siepmann T, Oertel R, Jung A, Ziemssen T, Jaehde U, Kirch W, Siepmann M. Pharmacokinetic/Pharmacodynamic Modeling of Venlafaxine: Pupillary Light Reflex as Test-system for Noradrenergic Effects. Clin Pharmacokinet 2008; 47: 721-731

Pieck AC, Drescher A, Wiesmann KG, Messerschmidt J, Weber G, Strumberg D, Hilger RA, Scheulen ME, Jaehde U. Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. Br J Cancer 2008; 98: 1959-1965

Klaassen T, Jetter A, Tomalik-Scharte D, Kasel D, Kirchheiner J, Jaehde U, Fuhr U. Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. Eur J Clin Pharmacol 2008; 64: 387-398

Baur M, Drescher A, Gneist M, Dittrich C, Jaehde U. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction. Cancer Chemother Pharmacol 2008; 61: 97-104

Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 2008; 283: 739-750

2007

Becker A, Vezmar S, Linnebank M, Pels H, Bode U, Schlegel U, Jaehde U. Marked elevation of homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Int J Clin Pharmacol Ther 2007; 45: 504-515

Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U. Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. Clin Pharmacokinet 2007; 46: 319-333

Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, Jaehde U. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 2007; 73: 298-307

Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, Jaehde U, Untch M, Kurbacher C, Fuhr U. Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther 2007; 81: 659-668

Schreiber D, Harlfinger S, Nolden BM, Gerth CW, Jaehde U, Schomig E, Klosterkotter J, Giuffrida A, Astarita G, Piomelli D, Leweke MF. Determination of anandamide and ohter fatty acyl ethanolamides in human serum by electrosspray tandem mass spectrometry. Anal Biochem 2007; 361: 162-168

2006

Greaves ED, Angeli-Greaves M, Jaehde U, Drescher A, von Bohlen A. Rapid determination of platinum plasma concentrations of chemotherapy patients using total reflection X-ray fluorescence. Spectrochim Acta B 2006; 61: 1194-1200

Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, Deuster D, Seifert E, Würthwein G, Jaehde U, Pieck AC, Boos J. Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 2006; 47: 183-193

2005

Ciarimboli G, Ludwig T, Lang D, Pavenstedt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167: 1477-1484

Rümelin A, Humbert T, Luhker O, Drescher A, Fauth U. Metabolic clearance of the antioxidant ascorbic acid in surgical patients. J Surg Res 2005; 129: 46-51

Rümelin A, Jaehde U, Kerz T, Roth W, Krämer M, Fauth U. Early postoperpative substitution procedure of the antioxidant ascorbic acid. J Nutr Biochem 2005; 16: 104-108

Liekweg A, Eckhardt M, Malfair Taylor SC, Erdfelder E, Jaehde U. Psychometric assessment and application of a questionnaire measuring patient satisfaction with information on cancer treatment. Pharm World Sci 2005; 27: 96-103

Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S, Strumberg D. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.  Anticancer Drugs 2005; 16: 129-136

2004

Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M, Kaina B. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 2004; 112: 974-985

Warnke U, Rappel C, Meier H, Kloft C, Galanski M, Hartinger CG, Keppler BK, Jaehde U. Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5'-monophosphate O6-N7 chelation. Chembiochem 2004; 5: 1543-1549

Warnecke A, Fichtner I, Garmann D, Jaehde U, Kratz F. Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug Carboplatin designed as albumin-binding prodrugs.  Bioconjug Chem 2004; 15: 1349-1359

Grasmäder K, Verwohlt PL, Kuhn KU, Dragicevic A, von Widdern O, Zobel A, Hiemke C, Rietschel M, Maier W, Jaehde U, Rao ML. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 2004; 60: 473-480

Weber G, Messerschmidt J, Pieck AC, Junker AM, Wehmeier A, Jaehde U. Ultratrace voltammetric determination of DNA-bound platinum in patients after administration of oxaliplatin. Anal Bioanal Chem 2004; 380: 54-58

2003

Kloft C, Siegert W, Jaehde U. Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer. Br J Cancer 2003; 89: 787-794

Grasmäder K, Jaehde U, Lohmann PL, Rao ML. Optimierung des TDM von Lithium durch computergestützte Dosisindividualisierung. Psychopharmakotherapie 2003; 10: 15-18